Gilead Announces Price of First COVID-19 Treatment Remdesivir

This post was originally published on this site

Drug manufacturer Gilead Sciences announced a price for its experimental COVID-19 treatment, remdesivir. In an open letter, Gilead announced that U.S. patients with private insurance will pay $520 per vial. With the majority of patients expected to receive …

Click here to read full article